{
    "clinical_study": {
        "@rank": "153040", 
        "arm_group": [
            {
                "arm_group_label": "FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET", 
                "arm_group_type": "Experimental", 
                "description": "FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once"
            }, 
            {
                "arm_group_label": "ANTADYS\u00ae and PEPCID\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "ANTADYS\u00ae 100 mg, PEPCID\u00ae 20 mg two tablets, taken once"
            }
        ], 
        "brief_summary": {
            "textblock": "To assess the bioequivalence of Test oral formulation of FLURBIPROFEN 100 mg FAMOTIDINE 20\n      mg MULTI-LAYER TABLET versus Reference ANTADYS\u00ae100 mg Comprim\u00e9 Pellicul\u00e9 & PEPCID\u00ae\n      (Famotidine) 20mg Tablets, USP."
        }, 
        "brief_title": "Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "An open-label, randomized, single dose, two-treatment, two-period, two-sequence, crossover\n      bioequivalence with a washout period of at least 7 days between doses Healthy mixed skin\n      Arab & Mediterranean Subjects ages between 18 and 45 years, body-mass index 18.5 to 30.0\n      kg/m2 inclusive, non-smokers or light smokers (smokers of not more than 10 cigarettes per\n      day)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy Male subjects.\n\n          2. Ethnic Group: Arab & Mediterranean\n\n          3. Race: Mixed skin (white & black skin people).\n\n          4. Age 18-45 years\n\n          5. Body-mass index 18.5 to 30.0 kg/m2 inclusive\n\n          6. Subject is available for the whole study period and gave written informed consent\n\n          7. Physical examination within normal ranges\n\n          8. All laboratory screening results within the normal range, or being assessed as\n             clinically non-significant by the attending physician.\n\n          9. Vital signs within normal ranges (Unless clinical investigator classified as\n             insignificant).\n\n         10. Normal Kidney & Liver function tests (Unless clinical investigator classified as\n             insignificant).\n\n         11. Normal Cardiovascular system.\n\n         12. Normal Digestive system.\n\n        Exclusion Criteria:\n\n          1. Women.\n\n          2. Ethnic Group (Non- Arab &/ or Non- Mediterranean)\n\n          3. History of severe allergy or allergic reactions to study drug or related drugs\n\n          4. Known history or presence of food allergies, or any condition known to interfere\n             with the  absorption, distribution, metabolism or excretion of drugs\n\n          5. History of serious illness that can impact fate of drugs\n\n          6. Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine,\n             musculoskeletal, neurological, hematological, liver or kidney disease, unless  judged\n             not clinically significant by the Principal Investigator, or medical  designate\n\n          7. Clinically significant illness 4 weeks before study Period I\n\n          8. Mental disease, drug, alcohol, solvents or caffeine abuse, smoking.\n\n          9. Regular use of medication\n\n         10. Having taken medication that could affect the investigated drug product: a) Regular\n             consumption of drugs during the two weeks prior to study initiation day, b)\n             consumption of enzyme stimulating or inhibiting drugs (e.g. Barbiturates,\n             Carbamazepine, Phenytoin) during one month before the study initiation.\n\n         11. Presence of any significant physical or organ abnormality\n\n         12. Donation of 1) at least 400 ml of blood within 60 days, or 2) more than 150 ml of\n             blood within 30 days, or 3) more than 100 ml blood plasma or platelets within 14\n             days before study Period I\n\n         13. Participation in another bioequivalence study within 80 days prior to the start of\n             this study Period I\n\n         14. Following a special diet (e.g. vegetarian) or dieting one month before the study\n             initiation.\n\n         15. History of Gastrointestinal diseases\n\n         16. Prior history of hypersensitivity to Flurbiprofen or Famotidine and other competitive\n             inhibitor of histamine H2-receptors.\n\n         17. Consumption of grapefruit or grapefruit containing products within 7 days of drug\n             administration\n\n         18. Ingestion of any vitamins or herbal products within 7 days prior to the initial dose\n             of the study medication.\n\n         19. Exhausting physical exercise in the last 48 hours (e.g. weight lifting) or any recent\n             significant change in dietary or exercise habits.\n\n         20. Any significant clinical abnormality including HBsAg, HCV, and HIV\n\n         21. Abnormal vital signs\n\n         22. Abnormal Kidney or Liver function tests.\n\n         23. Abnormal Cardiovascular system.\n\n         24. Abnormal Digestive system\n\n         25. Vomiting, Diarrhea."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910090", 
            "org_study_id": "FAFL439/PRO-00"
        }, 
        "intervention": [
            {
                "arm_group_label": "FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET", 
                "description": "MULTI-LAYER TABLET", 
                "intervention_name": "FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET", 
                "intervention_type": "Drug", 
                "other_name": "MULTI-LAYER TABLET"
            }, 
            {
                "arm_group_label": "ANTADYS\u00ae and PEPCID\u00ae", 
                "description": "ANTADYS\u00ae 100 mg, PEPCID\u00ae 20 mg two tablets, taken once", 
                "intervention_name": "ANTADYS\u00ae 100 mg, PEPCID\u00ae 20 mg", 
                "intervention_type": "Drug", 
                "other_name": "ANTADYS\u00ae 100 mg, PEPCID\u00ae 20 mg two tablets, taken once"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Famotidine", 
                "Flurbiprofen"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "fasting condition", 
        "lastchanged_date": "July 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Amman", 
                    "country": "Jordan", 
                    "zip": "00962"
                }, 
                "name": "Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit"
            }
        }, 
        "location_countries": {
            "country": "Jordan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel \u0130la\u00e7 San. ve Tic. A.\u015e., \u0130stanbul / T\u00fcrkiye) Versus ANTADYS\u00ae Flurbiprofen 100 mg Comprim\u00e9 Pellicul\u00e9 (One Film-coated Tablet) of (LaboratoireTh\u1ebbramex 6, Avenue Albert II- BP.59 98007 MONACO Cedex) and PEPCID\u00ae (Famotidine) 20 mg Tablets, USP (One Tablet) of (Marathon Pharmaceuticals, LLC USA) in Healthy Subjects Under Fasting Conditions", 
        "overall_official": [
            {
                "affiliation": "PRU", 
                "last_name": "Dr. Rana T. Bustami, Ph.D. of Pharmacy", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dr. Rana T. Bustami", 
                "last_name": "Dr. Rana T. Bustami, Ph.D. of Pharmacy", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Jordan: Jordan Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Cmax Ratio:  The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00% based on Flurbiprofen and Famotidine.\nAUC Ratio:  The 90% confidence interval for this measure lies within an acceptance range of 80.00% - 125.00% based on Flurbiprofen and Famotidine.", 
                "measure": "cmax", 
                "safety_issue": "No", 
                "time_frame": "five weeks"
            }, 
            {
                "measure": "tmax", 
                "safety_issue": "No", 
                "time_frame": "three weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910090"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pharmaceutical Research Unit, Jordan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmaceutical Research Unit, Jordan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}